Giant Biogene Holding Statistics

Total Valuation

Giant Biogene Holding has a market cap or net worth of HKD 49.96 billion. The enterprise value is 43.45 billion.

Market Cap	49.96B
Enterprise Value	43.45B

Important Dates

The next estimated earnings date is Tuesday, November 19, 2024.

Earnings Date	Nov 19, 2024
Ex-Dividend Date	Jun 17, 2024

Share Statistics

Giant Biogene Holding has 1.01 billion shares outstanding. The number of shares has decreased by -1.01% in one year.

Current Share Class	n/a
Shares Outstanding	1.01B
Shares Change (YoY)	-1.01%
Shares Change (QoQ)	+5.54%
Owned by Insiders (%)	57.76%
Owned by Institutions (%)	17.64%
Float	426.32M

Valuation Ratios

The trailing PE ratio is 25.63 and the forward PE ratio is 20.48.

PE Ratio	25.63
Forward PE	20.48
PS Ratio	10.05
PB Ratio	7.79
P/TBV Ratio	n/a
P/FCF Ratio	27.80
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.01, with an EV/FCF ratio of 24.18.

EV / Earnings	22.87
EV / Sales	9.07
EV / EBITDA	20.01
EV / EBIT	20.39
EV / FCF	24.18

Financial Position

The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.00.

Current Ratio	3.81
Quick Ratio	3.57
Debt / Equity	0.00
Debt / EBITDA	0.00
Debt / FCF	0.00
Interest Coverage	18,196.63

Financial Efficiency

Return on equity (ROE) is 37.14% and return on invested capital (ROIC) is 26.11%.

Return on Equity (ROE)	37.14%
Return on Assets (ROA)	21.27%
Return on Capital (ROIC)	26.11%
Revenue Per Employee	3.17M
Profits Per Employee	1.26M
Employee Count	1,164
Asset Turnover	0.76
Inventory Turnover	2.96

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +40.93% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+40.93%
50-Day Moving Average	48.38
200-Day Moving Average	43.91
Relative Strength Index (RSI)	41.97
Average Volume (20 Days)	3,416,451

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Giant Biogene Holding had revenue of HKD 4.79 billion and earned 1.90 billion in profits. Earnings per share was 1.93.

Revenue	4.79B
Gross Profit	3.96B
Operating Income	2.13B
Pretax Income	2.28B
Net Income	1.90B
EBITDA	2.17B
EBIT	2.13B
Earnings Per Share (EPS)	1.93

Full Income Statement

Balance Sheet

The company has 6.52 billion in cash and 1.57 million in debt, giving a net cash position of 6.51 billion or 6.45 per share.

Cash & Cash Equivalents	6.52B
Total Debt	1.57M
Net Cash	6.51B
Net Cash Per Share	6.45
Equity (Book Value)	6.42B
Book Value Per Share	6.36
Working Capital	5.30B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.02 billion and capital expenditures -220.01 million, giving a free cash flow of 1.80 billion.

Operating Cash Flow	2.02B
Capital Expenditures	-220.01M
Free Cash Flow	1.80B
FCF Per Share	1.78

Full Cash Flow Statement

Margins

Gross margin is 82.74%, with operating and profit margins of 44.48% and 39.65%.

Gross Margin	82.74%
Operating Margin	44.48%
Pretax Margin	47.65%
Profit Margin	39.65%
EBITDA Margin	45.28%
EBIT Margin	44.48%
FCF Margin	37.51%

Dividends & Yields

This stock pays an annual dividend of 0.48, which amounts to a dividend yield of 0.96%.

Dividend Per Share	0.48
Dividend Yield	0.96%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.01%
Shareholder Yield	1.96%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Giant Biogene Holding has an Altman Z-Score of 14.16.

Altman Z-Score	14.16
Piotroski F-Score	n/a